TY - JOUR AU - Davtyan, Hayk AU - Hovakimyan, Armine AU - Kiani Shabestari, Sepideh AU - Antonyan, Tatevik AU - Coburn, Morgan A. AU - Zagorski, Karen AU - Chailyan, Gor AU - Petrushina, Irina AU - Svystun, Olga AU - Danhash, Emma AU - Petrovsky, Nikolai AU - Cribbs, David H. AU - Agadjanyan, Michael G. AU - Blurton-Jones, Mathew AU - Ghochikyan, Anahit PY - 2019 DA - 2019/12/17 TI - Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice JO - Alzheimer's Research & Therapy SP - 107 VL - 11 IS - 1 AB - Alzheimer disease (AD) is characterized by the accumulation of beta-amyloid (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline. Current therapeutic approaches have primarily aimed to reduce pathological aggregates of either Aβ or tau, yet phase 3 clinical trials of these approaches have thus far failed to delay disease progression in humans. Strong preclinical evidence indicates that these two abnormally aggregated proteins interact synergistically to drive downstream neurodegeneration. Therefore, combinatorial therapies that concurrently target both Aβ and tau might be needed for effective disease modification. SN - 1758-9193 UR - https://doi.org/10.1186/s13195-019-0556-2 DO - 10.1186/s13195-019-0556-2 ID - Davtyan2019 ER -